Completed PHASE1 INTERVENTIONAL 2-arm NCT01872065

Safety and Tolerability Study of ARC-520 in Healthy Volunteers

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 in Normal Adult Volunteers

Sponsor: Arrowhead Pharmaceuticals

Conditions Healthy

Interventions ARC-520 Placebo

Updated 6 times since 2017 Last updated: Dec 19, 2025 Started: Jul 31, 2013 Primary completion: Sep 30, 2014 Completion: Nov 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01872065, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Arrowhead Pharmaceuticals, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1
Sep 2024 — Jan 2026 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arrowhead Pharmaceuticals

Data source: Arrowhead Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia